Minaris Advanced Therapies is a global CDMO and testing organization dedicated to advancing cell and gene therapies from development through commercial supply. With decades of experience, over 7,500 GMP batch releases, and commercial-ready facilities spanning three continents, we bring unmatched scale and expertise to our partners.
About the speaker
Jordan Lovett, Head of Commercial Development
Jordan Lovett is the Head of Commercial Development at Minaris Advanced Therapies’ Philadelphia site. He oversees the company’s portfolio of client sponsored cell-based therapy programs —including CAR-T, MSC, and TIL products—as well as gene therapies such as AAV, Adenovirus, HSV, and Lentiviral platforms. With a primary focus on late-phase and commercial-stage assets, Jordan has more than a decade of experience in cell and gene therapy business development. He holds a Master’s degree in Biomedical Sciences from Rowan University (formerly UMDNJ) and a Bachelor of Science in Biology from Saint Joseph’s University.